

[Open Peer Review on Qeios](#)

# Nafazatrom

National Cancer Institute

## Source

National Cancer Institute. *Nafazatrom*. NCI Thesaurus. Code C1010.

A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, which prolongs the biological half-life of prostacyclin (prostaglandin I<sub>2</sub>; PGI<sub>2</sub>) and prevents intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI<sub>2</sub>. An elevated level of PGI<sub>2</sub> prevents aggregation of platelets; subsequently it decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis.